Jortan Pharmaceuticals is Drug Discovery in United States that focus on pancreatic beta business. Founded in 2013. They cover business area such as developer, aspartic protease inhibitor, diabetes, pancreatic beta cell health, blood glucose level, healthcare provider, their patient, its harmful effect, heart disease, stroke, hypertension, kidney disease, retinal degeneration, neurological disease, hyperlipidemia.
2013
( 11 years old in 2024 )
Pancreatic Beta
-
865 Research Parkway
Suite 400, OU - University Research Park
Oklahoma City, OK 73104
United States
Private
developeraspartic protease inhibitordiabetespancreatic beta cell healthblood glucose levelhealthcare providertheir patientits harmful effectheart diseasestrokehypertensionkidney diseaseretinal degenerationneurological diseasehyperlipidemia
* We use standard office opening hours in near Jortan Pharmaceuticals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Jortan Pharmaceuticals is Drug Discovery business from United States that founded in 2013 (11 years old in 2024), Jortan Pharmaceuticals business is focusing on Pancreatic Beta.
Jortan Pharmaceuticals headquarter office and corporate office address is located in 865 Research Parkway Suite 400, OU - University Research Park Oklahoma City, OK 73104 United States.
Jortan Pharmaceuticals was founded in United States.
In 2024, Jortan Pharmaceuticals is currently focus on pancreatic beta sector.
Above is snippet of Google Trends for "pancreatic beta" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Jortan Pharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
